Add time:08/07/2019         Source:sciencedirect.com

BackgroundSepsis is a common diagnosis in critical care with inpatient mortality rates up to 50%. Sepsis care is organized around source control, antibiotics, and supportive care. Drug disposition is deranged by changes in volume of distribution and regional blood flow, as well as multiple organ failure. Thus, assuring that each patient with sepsis attains pharmacokinetic targets is challenging. There is currently no commercially available FDA-approved assay to measure piperacillin-tazobactam, very commonly used as a beta-lactam/beta-lactamase inhibitor combination antibiotic in the intensive care unit (ICU).

We also recommend Trading Suppliers and Manufacturers of Piperacillin-TazobactaM Powder 8:1 (cas 123683-33-0). Pls Click Website Link as below: cas 123683-33-0 suppliers